LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages XL Fleet Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – XL
April 10, 2021 10:00 ET | The Rosen Law Firm PA
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of XL Fleet Corp. (NYSE: XL) between October 2, 2020 and...
BL-new-logo.jpg
SOS SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Filed Against SOS Limited
April 10, 2021 09:24 ET | Bernstein Liebhard LLP
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities...
FStar.jpg
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
April 10, 2021 09:22 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
KTMC-Logo_RGB.jpg
Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Ebix, Inc.
April 10, 2021 09:09 ET | Kessler Topaz Meltzer & Check LLP
RADNOR, Pa., April 10, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States...
mersana_logo.png
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
April 10, 2021 09:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline – CYDY
April 10, 2021 09:00 ET | The Rosen Law Firm PA
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March...
Agenus Inc. Logo
New Clinical Responses for AGEN1181 Presented at AACR
April 10, 2021 08:35 ET | Agenus Inc.
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents ...
TCRR Logo.png
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
April 10, 2021 08:31 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
Arch Oncology Logo_RGB.jpg
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
April 10, 2021 08:31 ET | Arch Oncology
BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today...
Hookipa Pharma Logo Square.png
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
April 10, 2021 08:31 ET | Hookipa Pharma Inc
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an...